trial · primary record
Zasocitinib (Dose A)
Hidradenitis Suppurativa
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 90 |
| Primary completion | 2028-02-22 |
| Primary endpoint | Percentage of Participants who Achieve 75 Percent (%) Reduction in Hidradenitis Suppurativa Clinical Response (HiSCR75) |
| Registry ID | NCT07244263 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:58:47.948Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07244263
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.